APPLICATION NUMBER:
203098Orig1s000

PHARMACOLOGY REVIEW(S)
PHARMACOLOGY/TOXICOLOGY NDA REVIEW AND EVALUATION

Application number: N203098
Supporting document/s: \CDSESUB1\EVSPROD\NDA203098\203098.enx
Applicant's letter date: July 4, 2011
CDER stamp date: July 4, 2011
Review Completion: January 4, 2012

Product: Testosterone gel
Indication: Testosterone replacement in hypogonadal men
Applicant: Perrigo Israel Pharmaceuticals Ltd.
Review Division: DRUP
Reviewer: Jeffrey D. Bray, Ph.D.
Supervisor: Lynnda L. Reid, Ph.D.
Acting Deputy Division Director: Audrey Gassman, M.D.
Project Manager: Jeannie Roule

Disclaimer

Except as specifically identified, all data and information discussed below and necessary for approval of NDA 203098 are owned by Perrigo Israel Pharmaceuticals Ltd. or are data for which Perrigo Israel Pharmaceuticals Ltd. has obtained a written right of reference. Any information or data necessary for approval of NDA 203098 that Perrigo Israel Pharmaceuticals Ltd. does not own or have a written right to reference constitutes one of the following: (1) published literature, or (2) a prior FDA finding of safety or effectiveness for a listed drug, as reflected in the drug’s approved labeling. Any data or information described or referenced below from reviews or publicly available summaries of a previously approved application is for descriptive purposes only and is not relied upon for approval of NDA 203098.
# TABLE OF CONTENTS

1 EXECUTIVE SUMMARY ........................................................................................................... 3
   1.1 INTRODUCTION ........................................................................................................... 3
   1.2 BRIEF DISCUSSION OF NONCLINICAL FINDINGS ................................................ 3
   1.3 RECOMMENDATIONS ............................................................................................... 3

2 DRUG INFORMATION ........................................................................................................... 3
   2.1 DRUG ....................................................................................................................... 3
   2.2 RELEVANT IND/s, NDA/s, AND DMF/s ................................................................. 4
   2.3 DRUG FORMULATION ............................................................................................ 4
   2.4 COMMENTS ON NOVEL EXCIPIENTS .................................................................... 4
   2.5 COMMENTS ON IMPURITIES/DEGRADANTS OF CONCERN ............................... 5
   2.6 PROPOSED CLINICAL POPULATION AND DOSING REGIMEN ............................ 5
   2.7 REGULATORY BACKGROUND ................................................................................. 5

3 STUDIES SUBMITTED ......................................................................................................... 5

11 INTEGRATED SUMMARY AND SAFETY EVALUATION ........................................... 7

12 APPENDIX ....................................................................................................................... 7
1 Executive Summary

1.1 Introduction
This application is for a testosterone gel indicated for hypogonadal men. The applicant submitted a 505(b)(2) NDA application with reliance on the FDA's previous findings of safety and efficacy for similar products. This testosterone gel has a different formulation than other FDA-approved testosterone gels, but otherwise has no unique benefits or risks.

1.2 Brief Discussion of Nonclinical Findings
The applicant submitted no new nonclinical information, and is relying on published studies of testosterone and the FDA findings of safety and efficacy for AndroGel®, testosterone gel 1% (NDA 21-015) for Approval. Testosterone is the predominant male sex steroid produced by the testes and is responsible for adult male sexual characteristics. The overall toxicological profile of testosterone is well established. Nonclinical toxicities are not relevant for Approval due to the preponderance of clinical data for testosterone that supersedes any nonclinical findings. Literature references and a scientific rationale for the reliance on literature were submitted to support the nonclinical sections of the Labeling. While the formulation is different than other FDA-approved testosterone gel products, the components are at or below the levels in other FDA-approved products.

1.3 Recommendations

1.3.1 Approvability
Nonclinical data support Approval of testosterone gel for testosterone replacement in hypogonadal men.

1.3.2 Additional Non Clinical Recommendations
None.

1.3.3 Labeling
Class labeling is appropriate. No significant nonclinical labeling issues were identified nor are significant changes required.

2 Drug Information

2.1 Drug
CAS Registry Number: 5949-44-0

Generic Name: testosterone

Chemical Name: (17β)-17-hydroxyandrost-4-en-3-one
Molecular Formula/Molecular Weight:  C_{19}H_{28}O_{2}/288.42

Structure or Biochemical Description

\[
\text{Testosterone}
\]

Pharmacologic Class: androgen

2.2 Relevant IND/s, NDA/s, and DMF/s

- IND 107130 (Perrigo Israel, [b][4] testosteronr gel)
- NDA 21-105 (Solvay, AndroGel® 1% testosterone gel)
- NDA 22-309 (Abbott Labs, AndroGel® 1.62% testosterone gel)
- NDA 21-454 (Auxilliary, Testim® 1% testosterone gel)
- NDA 22-504 (AcruX, Axiron® 1% testosterone solution)
- NDA 202763 (Teva, 1% testosterone gel)

2.3 Drug Formulation

Product is delivered as 2.5 and 5 g sachets, or as a meter-dose pump that contains the identical drug product as the sachets. The meter-dose pump provides 1.25 g of drug product/actuation. The recommended starting dose is 5 g corresponding to 50 mg of testosterone and the dose can be titrated up to 10 g/day (100 mg testosterone).

### Composition of Testosterone Gel

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Function</th>
<th>Amount</th>
<th>Maximal Amount in Approved Products*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone, USP</td>
<td>API</td>
<td>100.0</td>
<td>(b)(4)</td>
</tr>
<tr>
<td>Alcohol, USP</td>
<td></td>
<td></td>
<td>(b)(4)</td>
</tr>
<tr>
<td>Isoeutaric Acid</td>
<td></td>
<td></td>
<td>(b)(4)</td>
</tr>
<tr>
<td>Carbomer 940, NF</td>
<td></td>
<td></td>
<td>(b)(4)</td>
</tr>
<tr>
<td>Carbopel 980, NF</td>
<td></td>
<td></td>
<td>(b)(4)</td>
</tr>
<tr>
<td>NaOH, NF</td>
<td></td>
<td></td>
<td>(b)(4)</td>
</tr>
<tr>
<td>Purified water, USP</td>
<td></td>
<td></td>
<td>(b)(4)</td>
</tr>
</tbody>
</table>

*In the Inactive Ingredient Database

2.4 Comments on Novel Excipients

A consult (b)(4) was performed to determine if the unqualified excipient for a gel product that differed in the applicant drug product from the RLD was of a toxicological concern (#2009-0331). It was deemed that the proposed use of the excipient Isoeutaric Acid (ISA) (b)(4) was acceptable from a pharm/tox perspective (See Appendix).
2.5 Comments on Impurities/Degradants of Concern

Impurities are below the specified limits of NMT. They

The sponsor obtained a Letter of Authorization from the holder of dated May 6, 2011. A review of the DMF shows

...with an acceptance criterion of NMT, which exceeds the ICH Q3B(R) guidance qualification limit of NMT 0.15%. The applicant provided a toxicological report in eCTD 3.2.S.4.5.1 that provides adequate characterization.

...The drug substance under this DMF has been used in other IND sponsors’ clinical trials.

2.6 Proposed Clinical Population and Dosing Regimen

Hypogonadal men will self-administer testosterone gel with 2.5 to 10 g of drug product daily to the shoulders/upper arms (abdomen was not evaluated). The starting dose is 5 g with the amount to be titrated based on achieving serum testosterone levels of 300-1000 ng/dL. Sachets can be used in combinations that equal the number of grams of gel prescribed.

2.7 Regulatory Background

The applicant previously submitted on June 15, 2007, for packets containing the same testosterone drug product. The applicant received a refusal to receive from on September 26, 2007, and responded plus added information about a multi-dose pump form on November 19, 2007. On January 23, 2008, another refusal to receive letter was sent to the applicant. The applicant responded to the letter on November 27, 2008, and also filed for multi-dose pump. In May 2009, both ANDAs were accepted for review. In August 2009, the applicant received Complete Response letters for both with advice to submit an NDA to DRUP. The applicant met with DRUP and then submitted IND 107130 on December 17, 2009. A meeting between the Division and the sponsor was held on May 19, 2010, to discuss the requirements for a 505(b)(2) NDA application.

The applicant submitted Form 356h with the 505(b)(2) box checked and a Reference List Drug listed as Androgel® (testosterone gel) 1%.

3 Studies Submitted

No studies were submitted or reviewed. The applicant submitted 16 literature references plus FDA references that establish the nonclinical toxicities of testosterone and support the nonclinical sections of the labeling.

1. FDA Meeting Minutes Dated May 19, 2010
2. Pharmacology Review for AndroGel® NDA 21-015

3. Prescribing Information for AndroGel®


11 Integrated Summary and Safety Evaluation

The overall toxicological profile of testosterone products is well established and both animals and humans exhibit similar toxicities. There are extensive nonclinical and clinical data with testosterone products including transdermal applications. Nonclinical data support approval of topical testosterone gel.  

12 Appendix
DIVISION OF REPRODUCTIVE AND UROLOGIC DRUG PRODUCTS
CONSULTATION (Tracking #69)
FOR INTERNAL USE WITHIN FDA ONLY

DATE: June 17, 2009
From: Jeffrey Bray, Ph.D.
Pharmacologist, DRUP
Through: Lynnda Reid, Ph.D.
Pharmacology Supervisor, DRUP
Scott Monroe, Ph.D.
Division Director, DRUP

To: Peter Chen
Consumer Safety Officer, OGD

Date of Consultation: May 12, 2009
RE: Consult No 2009-0331
Pharmacology/Toxicology Safety Review of Isostearic Acid (ISA)

Relevant DFM & ANDAs: NDA 21-015 (AndroGel®
1% testosterone gel), DMF # (4)

Recommended Regulatory Action

From a pharmacology/toxicology perspective, the proposed use of the excipient Isostearic Acid (ISA) at 1% is acceptable.
Introduction

The drug products under review are testosterone gel to treat men with primary and secondary hypogonadalism. Perrigo Israel Pharmaceuticals submitted which the Office of Generic Drugs initially refused to file partially based on the inclusion of the excipient Isostearic Acid (ISA) for the proposed topical transdermal gel route of administration since ISA is currently only in approved FDA products as topical creams and ointments. In response, the Sponsor provided a toxicological assessment of ISA prepared by Dr. Ron Filler. The report included the results of an extensive literature and web-based search conducted on the nonclinical toxicology, clinical safety information, and a comparative analysis to chemically similar C18 fatty acids. Also, the response contained a toxicological evaluation by the manufacturer of ISA, the Office of Generic Drugs requested a consult to evaluate the nonclinical data to ensure that the proposed inclusion of ISA in testosterone gel by Perrigo Israel is safe for human use.

Structure of Isostearic Acid

In general, ISA is a blend of branched chain saturated isomers of octadecanoic acid. ISA consists of approximately 80% branched chain C18 isomers of octadecanoic acid and 20% of straight chain isomers C14, C16, and C18 fatty acids. Chemical literature references use the term Isostearic Acid to refer specifically to 16- methylheptadecanoic acid (CAS Number 2724-58-5). ISA is prepared by dimerizing fatty acids from Tall oil, Soybean oil, or tallow in the presence of a catalyst. The reaction mix is fractionated and the monomer fraction is further refined by hydrogenation, solvent separation, and additional distillation.

<table>
<thead>
<tr>
<th>TABLE 1. Fatty Acid Components of Isostearic Acid.</th>
</tr>
</thead>
</table>

Table taken from Ref. 1.

Perrigo Israel Pharmaceuticals is proposing to use ISA instead of isopropyl myristate in its formulation of testosterone gel.
The daily exposure using the maximum recommended amount of 10 g AndroGel® 1% would be 20 mg of ISA.

### AndroGel® 1% (RLD)

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Function</th>
<th>%w/w</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone, USP</td>
<td>API</td>
<td>1.00</td>
</tr>
<tr>
<td>Alcohol, USP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isopropyl myristate, NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carbopol 980, NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NaOH, NF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purified water, USP</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The in vitro Frantz Cell System penetration profile using human cadaver skin is similar between RLD and ISA.

### Chart for formulation T06P033 versus the RLD

**Formulation with Isostearic acid in comparison to RLD**

**Review of Safety Data Provided in Assessment**
The ISA nonclinical toxicology and irritation and clinical irritation and sensitization studies were originally compiled by the Cosmetic, Toiletry and Fragrance Association (CTFA) before 1983 [1]. A more recent review of the toxicology of ISA was published in 2005 [2].

### Table of Contents

| Use of ISA in Topical Drugs and Cosmetics | 4 |
| Nonclinical Toxicity Studies with ISA | 6 |
| Metalsism | Acute Toxicity |
| Dermal Irritation | Phototoxicity |
| Mucous Membrane Irritation | Summary of Nonclinical Toxicity Studies with related C18 Fatty Acids | 7 |
| Stearic Acid | Oleic Acid |
| Summary of Computational Toxicology Consult | 9 |
| Nonclinical Summary | 10 |
| Clinical Studies with ISA | Irritation |
| Sensitization | Phototoxicity |
| Conclusion | 12 |

### Uses in Topical Drugs and Cosmetics

ISA is present at a concentration of in Aldara® (NDA 20-723, imiquimod 5% cream) [Chollet, 1999], and is listed in the IIG database as approved for the topical route of administration in concentrations of up to 25% . [3]

ISA is listed as an ingredient in topical and vaginal progesterone-containing creams, but the concentrations are not reported. Progesterone cream is categorized as an herbal beauty product, and as such these products are not regulated by the FDA.

ISA is used extensively in moisturizing cosmetics and shows similar physical properties as stearic acid and oleic acid, and is present in a wide variety of cosmetic products. There were 142 formulations reported to the FDA that contained ISA at concentrations from ≤0.1% to 10% in 1981 [1]. In 2005, the Annual Review of Cosmetic Ingredient Safety Assessment for 2002/2003 listed 119 formulations that reported containing ISA at concentrations from 0.003% to 26% [2].
**TABLE 13**

Historical and current cosmetic product uses and concentrations for Isostearic Acid

**COPYRIGHT PROTECTED MATERIAL**

Table taken from Ref. 2.
Nonclinical Toxicity [from Ref. 1]

Metabolism

Metabolism was investigated in mitochondrial and microsomal fractions of rat liver homogenate. In general, ISA is metabolized similar to other straight chain fatty acids. However, unlike straight chain fatty acids, ISA is oxidized to a large extent at the ω carbon to yield 3-carbon dicarboxylic acids, as well as successively at the β carbon to yield 2-carbon metabolites.

Acute Toxicity Studies

Five, single oral dose administration studies were conducted in rats. Three studies used undiluted ISA and 2 other studies used a product formulation containing ISA. The oral LD₅₀ is between 32 and 64 mL/kg (28.5 g/kg and 57 g/kg). There was mortality observed with clinical signs in a single study evaluating undiluted ISA at the two highest doses (28.5 g/kg and 57 g/kg) showing dose-dependent inhibition of locomotion and debilitation with nasal hemorrhage. Three of five animals died, and the other two were severely debilitated at 57 g/kg. The MTD was set at 28,500 mg/kg and the HED is approximately 28,000 mg/day.

Dermal Irritation

Five studies evaluating the potential for ISA to cause dermal irritation were conducted in rabbits using the Draize skin patch test procedure. Undiluted ISA (2 separate studies), 15% ISA in corn oil, and 3 product formations ranging from 1.24% to 35% were evaluated. In each study, 0.5 mL of test article was applied to bare skin and occluded for 24 h. The site was then graded for erythema and edema using the Draize scale. Undiluted ISA produced minimal irritation and ISA in corn oil was non-irritating. The product formations produced minimal to moderate irritation, and was suggested to be caused by other components of the formulations.

TABLE 5. Draize Primary Skin Irritation Tests on Isostearic Acid.

COPYRIGHT PROTECTED MATERIAL

Table taken from Ref. 1.
Phototoxicity

In a separate evaluation of dermal irritation and phototoxicity, 200 mg of undiluted ISA was applied to the dorsal side of New Zealand White rabbits for 2 h under a gauze pad on both sides of the animals. The right side patch was then removed and exposed to $5 \times 10^7$ ergs/cm black light (320-450 nm) while the left side patch was covered with aluminum foil. The investigators concluded that ISA was mildly irritating without light and moderately irritating with exposure to light, but the difference was not statistically significant.

Mucous Membrane Irritation (Eye)

Undiluted ISA and four product formulations containing 2-35% ISA were evaluated in modified or standard Draize eye irritation procedures. In each study, 0.1 ml of test article was instilled into the conjunctival sac of one eye of rabbits with no washing, with the untreated eye serving as a control. Irritation was graded according to the Draize scale after 1, 2, 3, 4, and 7 days. The undiluted ISA produced minimal transient irritation and the product formulations ranged from none to moderate, suggesting that other components were the irritant.

**TABLE 6.** Draize Eye Irritation Tests on Isostearic Acid.

<table>
<thead>
<tr>
<th>Copyright Protected Material Table Taken from Ref [1]</th>
</tr>
</thead>
</table>

Skin Corrosion Potential

The IntraAgency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) recommends ISA as a non-corrosive agent to use in *in vitro* TER tests used for the assessment of dermal corrosivity for the hazard potential of chemicals.

Summary of Nonclinical Toxicity Studies with related C18 Fatty Acids

The sponsor proposes that stearic and oleic acids are chemically and structurally similar to ISA, and thus toxicological findings can be used to bridge and support the safety of the closely related ISA. A report compiled extensively reviews the toxicology data for stearic acid and oleic acid from the literature.
Stearic acid [4,5,6]:
In rats, approximately 50% of liver radiocarbon was recovered as oleic acid after intravenous administration of $^{14}$C labeled stearic indicating that extensive desaturation occurred. Stearic acid is poorly absorbed.

Acute toxicity was assessed in mice by intraperitoneal injection ranging from 15 to 1500 mg/kg. The only finding of note was a loss of body weight at 1500 mg/kg.

In rats fed a diet of 50% stearic acid for 4 weeks, there were no observed adverse effects. In rats fed a diet of 50% stearic acid for 8 weeks, there were microscopic foreign body-type reactions in adipose tissues. Rats fed stearic acid at 50 g/kg for 24 weeks developed reversible lipogranulomas in adipose tissues. Rats fed 300 ppm of stearic acid for 30 weeks had increased mortality, and exhibited increased anorexia and pulmonary infections and diminished clotting times. Cats administered >5mg of stearic acid had elevated pulmonary but decreased systemic blood pressure with apnea and convulsions leading to death.

Stearic acid was not mutagenic in reverse mutation bacterial systems. Stearic acid was not evaluated in other standard genotoxicity assays.

Evaluation of stearic acid in reproductive toxicity assays was not reported.

Carcinogenicity potential was evaluated in four groups of mice. CFW Swiss Webster mice (n=16/group) were administered subcutaneous stearic acid in tricaprylin at 0.05 mg and 0.5 mg weekly for 26 injections. After 18 months, 10 and 6 mice were alive, respectively. Another group of mice (n=15) were administered 1 mg of stearic acid 3 times/week for 10 injections. At 12 and 18 months, there were 8 and 1 mice alive, respectively. Also, BALB/c mice were administered 1 mg of stearic acid 2 times/week for 82 injections. After 18 months, 7 mice were alive. No neoplasms were found in any of these groups.

However, neoplasms were found in 3 other groups BALB/c mice administered stearic acid in this investigation. The first group (n=15) was injected subcutaneously with 0.05 mg stearic acid twice weekly for 104 injections. After 18 months, 13 mice were alive. After 19 months, one pulmonary neoplasm was found. The second group of mice (n=10) received injections of 0.05 mg stearic acid twice weekly for 114 injections. After 18 months, four mice were alive. The incidences of sarcomas were 1, 2, and 1 after 6, 10, and 12 months, respectively, and 1 pulmonary neoplasm and 1 leukemia-lymphoma after 19 months. The third group of mice (n=10) received 0.5 mg stearic acid per subcutaneous injection twice weekly for 114 injections. After 18 months, 9 mice were alive. After 21 months, 1 pulmonary neoplasm and 1 adrenal carcinoma were found.

In a repeat of the first study using the ICR/Ha Swiss Millerton and CFW Swiss Webster mice, and administering subcutaneously stearic acid at 0.05 mg or 0.5 mg in 0.1mL tricaprylin. It was determined that stearic acid did not have carcinogenic activity, and that there were no sarcomas observed. The investigators stated that the previously observed sarcomas occurred at the injection sites, suggesting it was related to route of administration, not the stearic acid.
The systemic exposure of 600 mg of stearic acid at 45 h following dermal application seems to be very limited using radioactive stearic acid in rat skin with most of the radioactive material appearing to remain on the surface of the skin.

Oleic acid [4,5]:
Oleic acid appears to have limited ability to penetrate the skin of rats and the path is suggested to be via hair follicles. Oleic acid has a T1/2 of approximately 200 days. During the first 4 days following administration, half of the activity is fixed to water and half is stored in adipose tissue.

Acute toxicity was not reported.

Pulmonary findings were observed in dogs receiving weekly injections of 90 mg/kg oleic acid for 1-3 months. Early changes including thromboses and cellular necrosis followed by a repair stage with type 2 cell proliferation and fibrotic foci in subpleural areas. Pulmonary fibrosis was observed later.

Weanling rats fed a diet of 15% oleic acid for 10-16 weeks had no adverse growth effects. Four females became pregnant, two died in parturition; one litter was cannibalized at birth and the remaining litter dies within 3 days of birth after the dams were fed 15% oleic acid for 16 weeks. Female rats (n=7) fed a diet of 15% oleic acid for 16 weeks and then mated produced offspring, 44 of which survived 1 week and 11 of which survived 3 weeks. Findings of note were retarded mammary development and ovarian cysts. No lesions were found in non-reproductive organs.

Oleic acid was not mutagenic in reverse mutation bacterial systems. Oleic acid increased aneuploidy in the D6 strain of *S. cerevisiae* up to 50 µg/ml and V79 CHL fibroblasts at 2.5, 5 and 100 µg/ml.

Oleic acid was evaluated for carcinogenic potential in two investigations. In the first study, Swiss Webster mice (n=15) given subcutaneous injections of 0.1 mg of 1 mg/ml oleic acid in tricaprylin 3 times/week for 10 injections. After 12 months, 9 mice were alive, and after 18 months, 1 mouse was alive. No neoplasms were observed after this treatment. In the second investigation, Swiss-Webster mice (n=16) were administered 0.5 mg oleic acid with 2 injections /week for 33 injections. After 12 months, 8 mice were alive, and after 18 months, 4 were alive. One mammary gland carcinoma was found after 9 months. Oleic acid was deemed to be noncarcinogenic.

**Summary and Assessment of Nonclinical Toxicology Results**

In general, topically applied ISA, undiluted or as part of a product formulation, was minimally irritating in standard assays that evaluate dermal irritation. There was no evidence of phototoxicity or eye irritation. The acute oral toxicity of ISA is low in rats requiring very large amounts before morbidity and mortality were observed (HED is approximately 27,600 g). The human daily dermal exposure is 0.02 mg, thus representing low overall exposure compared to animal testing. However, the pharmacokinetics, the chronic toxicology, and the potential genotoxicity, carcinogenicity, and reproductive/developmental toxicology of ISA have not been
directly assessed. A computational toxicology consult determined that ISA is predicted to have potential genotoxicity in some models and mouse sperm toxicity. Of interest, ISA was specifically predicted to have low or no toxicity in most common toxicity assays and models. The sponsor provided a safety assessment of the related C18 fatty acids, stearic acid and oleic acid. These are minor components in the ISA formulation (Table 1, page 2). In general, the toxic potential of stearic acid and oleic acid appears low and the most significant findings were related to pulmonary findings after chronic oral or parenteral, but not topical, administration.

Clinical Studies with ISA[1]

Dermal Irritation

Five clinical studies evaluating the potential for ISA to cause dermal irritation were conducted using the 24 h dermal occlusion patch test procedure. One study used undiluted ISA with 100 subjects and the other studies used product formulations containing 0.44% to 35% ISA. All amounts are at least 2X the amount proposed by the sponsor. The undiluted ISA was graded to be negative in causing dermal irritation. A single study was graded as minimal irritation, possibly caused by other components of the formulation.

Table 7. Clinical 24-Hour Single Insult Patch Tests with Isostearic Acid.

COPYRIGHT PROTECTED MATERIAL

Table taken from Ref. 1.

Sensitization

Four clinical studies evaluating the potential for ISA to cause dermal irritation and sensitization were conducted using a repeated insult patch test procedure. The amount of ISA used in these studies ranged from 5 to 30 mg. Two studies used ISA diluted in mineral oil and two studies used product formulations containing 0.2% and 0.44% ISA. The methodologies of the first two studies were slightly different. In the first study, 0.1 ml of 35% ISA was applied on the back of subjects at 48 h intervals for 3/week for 3 weeks before removal. The area was occluded for the
first 24 h, then washed. The test sites were graded at 48 h, then a fresh application was placed on the site. Following a 3-week nontreatment period, the test site and another previously untreated site had test article applied as above. The sites were graded at 24, 48, and 72 h. There were transient reactions observed, but the evaluators concluded that that ISA was not an irritant or a sensitizer. In the second study using 10% ISA in mineral oil, Test article was applied to the back and semi-occluded for 48 h (or 72 h on weekends). The patch was removed, the site graded and test article reapplied. This was repeated 10 times, followed by a nontreatment period of 2 weeks. There was a rechallenge as above, then the site was graded. The evaluators reported no irritation or sensitization. The formulation studies observed no irritation or sensitization.

**TABLE 8.** Clinical Repeated Insult Patch Tests with Isostearic Acid.

<table>
<thead>
<tr>
<th>COPYRIGHT PROTECTED MATERIAL</th>
</tr>
</thead>
</table>

Table taken from Ref. 1.

**Phototoxicity**

In the same sensitization study that used 35% ISA, phototoxicity was examined in 28 subjects. The procedure was the same as above except the forearm was used as the test site. The subjects were divided into 2 groups that received UVA only (n=19) or UVA and UVB light (n=9). Those receiving UVA had UVA light (320-400 nm) was applied to the test site for 15 min at 4.4 μW/cm² at the skin surface. Those receiving both had UVB light applied to the test site at two times the mean erythema dose (280-320 nm) and also received UVA for 5 min as previously described. There were transient reactions observed, but the evaluators concluded that that ISA was not phototoxic.

**Conclusion:**

Below are the conclusions from the published safety assessments of ISA.

“On the basis of the available information presented in this report, the Panel concludes that Isostearic Acid is safe as a cosmetic ingredient in the present practice of use.” [1]

“A safety assessment of Isostearic Acid was published in 1983 with the conclusion: “safe as a cosmetic ingredient in the present practice of use” (Elder 1983). Studies available since that safety assessment was completed, along with updated information regarding uses and concentrations were considered by the CIR Expert Panel. The Panel determined to not reopen this safety assessment.” [2]
ISA is a common ingredient in hundreds of cosmetic products with decades of human use up to 200 times the proposed concentration. Fatty acids including ISA are a component of many vegetable and animal food products. The limited nonclinical toxicology data (mainly dermal) and clinical safety data support the findings that ISA appears to be safe for use as an excipient in all manners of topical formulations with similar findings. In fact, 100% ISA was often found to be less of an irritant or sensitizer than formulations that had much lower concentrations. Further, two closely related fatty acids that are found in ISA as minor components did not appear to have significant nonclinical toxicities.

From a Pharm/Tox perspective, there is adequate nonclinical and clinical safety information to support the use of Isostearic Acid in testosterone gel.

References

4. National Library of Medicine, TOXNET, Hazardous Substance Data Bank
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JEFFREY D BRAY
01/27/2012

LYNNDAL REID
01/30/2012
Concur.
PHARMACOLOGY/TOXICOLOGY CHECKLIST FOR A NEW NDA/BLA

NDA Number: 203098  Applicant: Perrigo  Stamp Date: July 5, 2011
Drug Name: testosterone gel  NDA Type: 505(b)2

60-Day Filing Review Date: September 3, 2011
74-Day Letter Date: September 17, 2011
Expected Date of Draft Review: December 1, 2011
PDUFA Goal date: May 5, 2012

On initial overview of the NDA application for RTF:

<table>
<thead>
<tr>
<th>Content Parameter</th>
<th>Yes</th>
<th>No</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 On its face, is the pharmacology/toxicology section of the NDA organized (in</td>
<td>X</td>
<td></td>
<td>The applicant performed no nonclinical studies, but submitted a justification for the 505(b)(2) pathway with literature to support</td>
</tr>
<tr>
<td>accord with 21 CFR 314 and current guidelines for format and content) in a manner</td>
<td></td>
<td></td>
<td>the nonclinical sections of the labeling. Reference listed drug: AndroGel 1%</td>
</tr>
<tr>
<td>to allow substantive review to begin?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Is the pharmacology/toxicology section of the NDA indexed and paginated in a</td>
<td>n/a</td>
<td></td>
<td>See above.</td>
</tr>
<tr>
<td>manner allowing substantive review to begin?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 On its face, is the pharmacology/toxicology section of the NDA legible so that</td>
<td>n/a</td>
<td></td>
<td>See above.</td>
</tr>
<tr>
<td>substantive review can begin?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Are all required (*) and requested IND studies (in accord with 505 b1 and b2</td>
<td>X</td>
<td></td>
<td>See above.</td>
</tr>
<tr>
<td>including referenced literature) completed and submitted in this NDA (carcinogenicity,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mutagenicity*, teratogenicity*, effects on fertility, juvenile studies, acute and</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>repeat dose adult animal studies*, animal ADME studies, safety pharmacology, etc)?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 If the formulation to be marketed is different from the formulation used in the</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>toxicology studies, have studies by the appropriate route been conducted with</td>
<td>n/a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>appropriate formulations? (For other than the oral route, some studies may be by</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>routes different from the clinical route intentionally and by desire of the FDA).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 On its face, does the route of administration used in the animal studies appear</td>
<td>n/a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Content Parameter</td>
<td>Yes</td>
<td>No</td>
<td>Comment</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------------</td>
<td>-----</td>
<td>----</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>7 Has the sponsor submitted a statement(s) that all of the pivotal pharm/tox studies have been performed in accordance with the GLP regulations (21 CFR 58) or an explanation for any significant deviations?</td>
<td>n/a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 Has the sponsor submitted all special studies/data requested by the Division during pre-submission discussions with the sponsor?</td>
<td>n/a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 Are the proposed labeling sections relative to pharmacology/toxicology appropriate (including human dose multiples expressed in either mg/m2 or comparative serum/plasma levels) and in accordance with 201.57?</td>
<td>X</td>
<td></td>
<td>Labeling consistent with other testosterone gels will be applied.</td>
</tr>
<tr>
<td>10 If there are any impurity – etc. issues, have these been addressed? (New toxicity studies may not be needed.)</td>
<td>n/a</td>
<td></td>
<td>No issues have been identified; sponsor is using excipients ≤ amounts in FDA Inactive Ingredient Database or FDA-approved products.</td>
</tr>
<tr>
<td>11 Has the sponsor addressed any abuse potential issues in the submission?</td>
<td>X</td>
<td></td>
<td>Ensure consistency among transdermal T products in labeling on potential abuse.</td>
</tr>
<tr>
<td>12 If this NDA is to support a Rx to OTC switch, have all relevant studies been submitted?</td>
<td>n/a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13 From a pharmacology/toxicology perspective, is the NDA fileable? If ‘‘no’’ please state below why it is not.</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Any Additional Comments: none

Jeffrey Bray, Ph.D. 9/1/2011
Reviewing Pharmacologist

Lynnda Reid, Ph.D. 9/1/2011
Team Leader/Supervisor
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JEFFREY D BRAY
09/01/2011

LYNNDAL REID
09/01/2011